Who is the CEO of Jetema?

According to the DART company overview, Jetema's representative director is 남정선 (name as registered in Korean). The company was founded on 2009-07-17.

Where is Jetema listed?

Jetema trades on the Korea Exchange KOSDAQ market under the ticker 216080. Its fiscal year ends in December.

Does Jetema pay a dividend?

Jetema did not pay a cash dividend for fiscal 2025, according to its annual report.

Does Jetema have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Insider selling (officers or major shareholders reported cutting shares (30 days)); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Major holder adding (a 5%+ shareholder reported raising its stake (30 days)); Supply contract (single sales or supply contract disclosed in the past 30 days). These are factual flags, not investment advice.

Which companies are in the same industry as Jetema?

Under the Korean Standard Industrial Classification recorded on DART, Jetema is grouped with 31 other listed companies in medical supplies. The most covered in Korean news over the past 30 days are HLB, PharmaResearch and Rokit Healthcare.

Jetema KRX:216080KOSDAQ

제테마 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days1

Articles tracked28since Sep 11

In Q2 2026, Jetema reported revenue of ₩20.1bn, down 2.4% year on year, and operating profit of ₩2.3bn. Jetema (제테마) appeared in 0 Korean news articles and 1 DART filing over the past seven days.

Filing signals Major holder adding Supply contract Insider selling Share pledge Screener

Jetema quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩20.1bn	-2.4%	₩2.3bn margin 11.5%	₩1.4bn
Q1 2026	₩16.0bn	+1.1%	−₩665m margin −4.2%	−₩2.4bn
Q4 2025 derived	₩20.4bn	+7.1%	₩1.2bn margin 5.8%	₩1.9bn
Q3 2025	₩20.1bn	+34.5%	₩1.0bn margin 5.1%	−₩2.8bn
Q2 2025	₩20.6bn	+18.9%	₩1.8bn margin 8.6%	−₩2.5bn
Q1 2025	₩15.8bn	-8.1%	−₩144m margin −0.9%	−₩4.1bn
Q4 2024 derived	₩19.0bn	+25.2%	−₩14m margin −0.1%	₩3.3bn
Q3 2024	₩15.0bn	+5.7%	₩244m margin 1.6%	−₩3.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Jetema top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest Jetema news Korean headlines

Oct 1609:21

'국산 비만약 1호' 한미약품 출격…중외·이노엔·제테마도 도전
PRESS9Hanmi Pharm
Oct 1515:28
Major제테마, 톡신·필러 402억원 규모 독점 공급계약
이데일리Order / supply contract
3 more on this story · 3 outlets
- 제테마, 톡신·필러 402억원 규모 독점 공급계약이데일리증권 · Oct 15 15:28
- 제테마, 톡신·필러 402억원 규모 독점 공급계약이데일리 · Oct 15 15:28
- [공시] 제테마, 301억원 규모 톡신 독점 공급계약 체결현대경제신문 · Oct 15 15:37
Oct 1513:45
Major[공시] 제테마 단일판매ㆍ공급계약체결
스페셜타임스Order / supply contract
1 more on this story · 1 outlets
- [공시] 제테마 단일판매ㆍ공급계약체결스페셜타임스 · Oct 15 14:16
Oct 1513:42

MajorBreaking제테마, 301억5000만원 규모 톡신 독점공급 계약
CBC뉴스Order / supply contract
Oct 1414:15
제테마, 보툴리눔 톡신 태국 수출 시작
조선비즈
1 more on this story · 1 outlets
- 제테마, 보툴리눔 톡신 태국 수출 시작조선일보 · Oct 14 14:22
Oct 1413:46
제테마, 보툴리눔 톡신 태국 첫 출고...5년간 65만 바이알 공급 추진
파이낸셜뉴스
1 more on this story · 1 outlets
- 제테마, 보툴리눔 톡신 태국 첫 출고…연내 판매 추진스페셜타임스 · Oct 14 14:31
Oct 1411:40
제테마, '제테마더톡신' 태국 첫 수출 선적…동남아 시장 진출
메디파나뉴스
1 more on this story · 1 outlets
- 제테마, '제테마더톡신' 태국 첫 수출뉴스핌 · Oct 14 14:57
Oct 1216:31

제테마, 닥터레디와 손잡고 GLP-1 비만 치료제 국내 도입 추진
EBNPartnership
Oct 1215:41

제테마, 닥터레디 손잡고 GLP-1 비만치료제 국내 도입…2028년 상용화 시동
와이드경제
Oct 1214:43
Major제테마, '닥터레디' GLP-1 비만약 국내공급 계약
뉴시스경제Order / supply contract
1 more on this story · 1 outlets
- 제테마, 닥터레디와 GLP-1 비만약 계약뉴스핌 · Oct 12 14:51
Oct 1213:09

제테마, 닥터레디와 비만약 독점계약…3년차 예상수요 2000만달러
메디코파마
Oct 1209:51
Major제테마, 인도 닥터레디와 비만약 국내 공급 계약…2028년 출시 목표
조선비즈Order / supply contract
1 more on this story · 1 outlets
- 제테마, 인도 닥터레디와 비만약 국내 공급 계약…2028년 출시 목표조선일보 · Oct 12 09:55
Oct 1209:47
제테마, 글로벌 제약사 닥터레디와 GLP-1 비만치료제 국내 공급 '맞손'
프라임경제글로벌테크놀로지
4 more on this story · 4 outlets
- 제테마, 닥터레디와 GLP-1 비만치료제 국내 공급 계약…2028년 상업화 목표더바이오 · Oct 12 10:07
- 제테마, GLP-1 비만치료제 국내 도입…닥터레디와 공급 계약PRESS9 · Oct 12 10:12
- 제테마, 닥터레디와 GLP-1 비만치료제 국내 공급 계약…2028년 상업화 추진바이오타임즈 · Oct 12 12:10
- 제테마, 닥터레디와 손잡고 GLP-1 비만치료제 국내 도입스페셜타임스 · Oct 12 19:03
Sep 1415:27

제테마 子 그로젠바이오, DEB 유전자치료제 비임상 본격화…유럽 기관과 협력
PRESS9
Sep 1109:58

제테마, 태국서 ASLS·카데바 워크숍 개최
뉴스핌

Articles per day 2 weeks

Company profile

CEO: 남정선
Industry: Medical supplies
Founded: 2009-07-17
Fiscal year-end: December
Head office: 강원도 원주시
Website: jetema.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

김재영28.94%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Medical supplies

All in industry

Company	Latest quarter op. profit	Articles 30d
HLB	−₩22.5bn	310
PharmaResearch	₩66.5bn	129
Rokit Healthcare	−₩13.5bn	79
Seegene	₩21.6bn	44
AbClon	−₩6.3bn	23
SCL Science	₩406m	23
Nibec	₩103m	17
Asta	−₩839m	16

Compare Jetema side by side with these companies

Jetema DART filings

Oct 2909:21

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Oct 2110:33

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Oct 1513:41

Supply contract 단일판매ㆍ공급계약체결
Contracts & investment
Oct 1513:41

Supply contract 단일판매ㆍ공급계약체결
Contracts & investment
Oct 1214:34

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Sep 3017:41

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 3017:34

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports
Sep 3017:10

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 2817:26

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 2817:24

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 2117:27

Insider ownership report 임원ㆍ주요주주특정증권등소유상황보고서
Ownership reports
Sep 1515:44

5% ownership report 주식등의대량보유상황보고서(일반)
Ownership reports

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Jetema FAQ

Who is the CEO of Jetema?: According to the DART company overview, Jetema's representative director is 남정선 (name as registered in Korean). The company was founded on 2009-07-17.
Where is Jetema listed?: Jetema trades on the Korea Exchange KOSDAQ market under the ticker 216080. Its fiscal year ends in December.
What were Jetema's latest quarterly results?: In Q2 2026, Jetema reported revenue of ₩20.1bn, down 2.4% year on year, and operating profit of ₩2.3bn. Figures come from reports filed on DART.
Does Jetema pay a dividend?: Jetema did not pay a cash dividend for fiscal 2025, according to its annual report.
Does Jetema have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Insider selling (officers or major shareholders reported cutting shares (30 days)); Share pledge (a 5%+ holder reported a share pledge agreement (loan, extension or change) in the past 90 days); Major holder adding (a 5%+ shareholder reported raising its stake (30 days)); Supply contract (single sales or supply contract disclosed in the past 30 days). These are factual flags, not investment advice.
Which companies are in the same industry as Jetema?: Under the Korean Standard Industrial Classification recorded on DART, Jetema is grouped with 31 other listed companies in medical supplies. The most covered in Korean news over the past 30 days are HLB, PharmaResearch and Rokit Healthcare.